Literature DB >> 29502154

The impact of UGT2B7 C802T and CYP3A4*1G polymorphisms on pain relief in cancer patients receiving oxycontin.

Jingwen Li1, Peng Peng2, Qi Mei3, Shu Xia3, Yijun Tian3, Liya Hu3, Yuan Chen4.   

Abstract

BACKGROUND: Single nucleotide polymorphisms (SNPs) in UGT2B7 C802T and CYP3A4*1G impact drug metabolism. This study aimed to investigate the impact of these SNPs on the efficacy of oxycontin for pain relief in cancer patients.
METHODS: A total of 57 Han Chinese cancer patients (age range 20-70 years) who received oxycontin to ease pain for the first time were enrolled and divided into two groups (refractory group and remission group) according to pain relief. Peripheral blood samples were collected from each patient for sequencing analysis. The genotype and allele frequency between the two groups were analyzed using the chi-square test.
RESULTS: The T allele frequency of UGT2B7 C802T was 25% among all participants, but was higher (32%) in the refractory group (P = 0.047). The variant allele frequency of CYP3A4*1G was 27% and did not differ between the refractory group and remission group.
CONCLUSION: The palliative effect of oxycontin is better in patients with UGT2B7 802CC than in those with 802TT. CYP3A4*1G SNP is unlikely to affect pain relief efficacy of oxycontin.

Entities:  

Keywords:  CYP3A4*1G; Oxycontin; Pain; SNPs; UGT2B7 C802T

Mesh：

Substances：

Year:  2018        PMID： 29502154     DOI： 10.1007/s00520-018-4130-4

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN： 0941-4355            Impact factor:   3.603


  15 in total

1.  Haplotypes of CYP3A4 and their close linkage with CYP3A5 haplotypes in a Japanese population.

Authors:  Hiromi Fukushima-Uesaka; Yoshiro Saito; Hidemi Watanabe; Kisho Shiseki; Mayumi Saeki; Takahiro Nakamura; Kouichi Kurose; Kimie Sai; Kazuo Komamura; Kazuyuki Ueno; Shiro Kamakura; Masafumi Kitakaze; Sotaro Hanai; Toshiharu Nakajima; Kenji Matsumoto; Hirohisa Saito; Yu-ichi Goto; Hideo Kimura; Masaaki Katoh; Kenji Sugai; Narihiro Minami; Kuniaki Shirao; Tomohide Tamura; Noboru Yamamoto; Hironobu Minami; Atsushi Ohtsu; Teruhiko Yoshida; Nagahiro Saijo; Yutaka Kitamura; Naoyuki Kamatani; Shogo Ozawa; Jun-ichi Sawada
Journal:  Hum Mutat       Date:  2004-01       Impact factor: 4.878

Review 2.  Pharmacogenetics of opioids.

Authors:  Andrew A Somogyi; Daniel T Barratt; Janet K Coller
Journal:  Clin Pharmacol Ther       Date:  2007-03       Impact factor: 6.875

3.  Human UGT2B7 catalyzes morphine glucuronidation.

Authors:  B L Coffman; G R Rios; C D King; T R Tephly
Journal:  Drug Metab Dispos       Date:  1997-01       Impact factor: 3.922

Review 4.  Biological pathways and genetic variables involved in pain.

Authors:  Qiuling Shi; Charles S Cleeland; Pål Klepstad; Christine Miaskowski; Nancy L Pedersen
Journal:  Qual Life Res       Date:  2010-09-15       Impact factor: 4.147

5.  Effect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled study.

Authors:  Juha Grönlund; Teijo I Saari; Nora M Hagelberg; Pertti J Neuvonen; Kari Laine; Klaus T Olkkola
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.

Authors:  Bojan Lalovic; Evan Kharasch; Christine Hoffer; Linda Risler; Lee-Yuan Liu-Chen; Danny D Shen
Journal:  Clin Pharmacol Ther       Date:  2006-05       Impact factor: 6.875

Review 7.  Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs.

Authors:  Kazuya Maeda; Yuichi Sugiyama
Journal:  Drug Metab Pharmacokinet       Date:  2008       Impact factor: 3.614

8.  Relationship between response to risperidone, plasma concentrations of risperidone and CYP3A4 polymorphisms in schizophrenia patients.

Authors:  J Du; A Zhang; L Wang; J Xuan; L Yu; R Che; X Li; N Gu; Z Lin; G Feng; Q Xing; L He
Journal:  J Psychopharmacol       Date:  2009-04-24       Impact factor: 4.153

9.  Association of UGT2B7 and ABCB1 genotypes with morphine-induced adverse drug reactions in Japanese patients with cancer.

Authors:  Ken-ichi Fujita; Yuichi Ando; Wataru Yamamoto; Toshimichi Miya; Hisashi Endo; Yu Sunakawa; Kazuhiro Araki; Keiji Kodama; Fumio Nagashima; Wataru Ichikawa; Masaru Narabayashi; Yuko Akiyama; Kaori Kawara; Mari Shiomi; Hiroyasu Ogata; Hiroyasu Iwasa; Yasushi Okazaki; Takashi Hirose; Yasutsuna Sasaki
Journal:  Cancer Chemother Pharmacol       Date:  2010-01       Impact factor: 3.333

10.  Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients.

Authors:  G R Lauretti; G M Oliveira; N L Pereira
Journal:  Br J Cancer       Date:  2003-12-01       Impact factor: 7.640
View more
  3 in total

Review 1.  SULT genetic polymorphisms: physiological, pharmacological and clinical implications.

Authors:  Katsuhisa Kurogi; Mohammed I Rasool; Fatemah A Alherz; Amal A El Daibani; Ahsan F Bairam; Maryam S Abunnaja; Shin Yasuda; Lauren J Wilson; Ying Hui; Ming-Cheh Liu
Journal:  Expert Opin Drug Metab Toxicol       Date:  2021-06-30       Impact factor: 4.936

2.  Impact of CYP3A4*1G Polymorphism on Fentanyl Analgesia Assessed by Analgesia Nociception Index in Chinese Patients Undergoing Hysteroscopy.

Authors:  Qi Yan; Yi Su; Lan Gao; Nan Ding; Hong-Ying Zhang; Wen E; Yue Wang; Yi Feng; Hai-Yan An
Journal:  Chin Med J (Engl)       Date:  2018-11-20       Impact factor: 2.628

Review 3.  Pharmacogenomics and Morphine.

Authors:  Adaku Ofoegbu; Earl B Ettienne
Journal:  J Clin Pharmacol       Date:  2021-06-16       Impact factor: 3.126
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.